Clinical outcomes of patients receiving prolonged extracorporeal membrane oxygenation for respiratory support

Background: There are limited data regarding prolonged extracorporeal membrane oxygenation (ECMO) support, despite increase in ECMO use and duration in patients with respiratory failure. The objective of this study was to investigate the outcomes of severe acute respiratory failure patients supporte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutic advances in respiratory disease 2019-01, Vol.13, p.1753466619848941
Hauptverfasser: Na, Soo Jin, Jung, Jae-Seung, Hong, Sang-Bum, Cho, Woo Hyun, Lee, Sang-Min, Cho, Young-Jae, Park, Sunghoon, Koo, So-My, Park, Seung Yong, Chang, Youjin, Kang, Byung Ju, Kim, Jung-Hyun, Oh, Jin Young, Park, So Hee, Yoo, Jung-Wan, Sim, Yun Su, Jeon, Kyeongman
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: There are limited data regarding prolonged extracorporeal membrane oxygenation (ECMO) support, despite increase in ECMO use and duration in patients with respiratory failure. The objective of this study was to investigate the outcomes of severe acute respiratory failure patients supported with prolonged ECMO for more than 28 days. Methods: Between January 2012 and December 2015, all consecutive adult patients with severe acute respiratory failure who underwent ECMO for respiratory support at 16 tertiary or university-affiliated hospitals in South Korea were enrolled retrospectively. The patients were divided into two groups: short-term group defined as ECMO for ⩽28 days and long-term group defined as ECMO for more than 28 days. In-hospital and 6-month mortalities were compared between the two groups. Results: A total of 487 patients received ECMO support for acute respiratory failure during the study period, and the median support duration was 8 days (4–20 days). Of these patients, 411 (84.4%) received ECMO support for ⩽28 days (short-term group), and 76 (15.6%) received support for more than 28 days (long-term group). The proportion of acute exacerbation of interstitial lung disease as a cause of respiratory failure was higher in the long-term group than in the short-term group (22.4% versus 7.5%, p 
ISSN:1753-4666
1753-4658
1753-4666
DOI:10.1177/1753466619848941